ELI-CEL Trademark

Trademark Overview

On Friday, February 12, 2021, a trademark application was filed for ELI-CEL with the United States Patent and Trademark Office. The USPTO has given the ELI-CEL trademark a serial number of 79309143. The federal status of this trademark filing is REGISTERED as of Tuesday, July 26, 2022. This trademark is owned by Bluebird Bio (UK) Ltd.. The ELI-CEL trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of genetic diseases, namely, adrenoleukodystrophy and adrenomyeloneuropathy
eli-cel

General Information

Serial Number79309143
Word MarkELI-CEL
Filing DateFriday, February 12, 2021
Status700 - REGISTERED
Status DateTuesday, July 26, 2022
Registration Number6799494
Registration DateTuesday, July 26, 2022
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 10, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of genetic diseases, namely, adrenoleukodystrophy and adrenomyeloneuropathy

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, April 23, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party Namebluebird bio, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressUS
Party NameBluebird Bio, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressUS
Party NameBluebird Bio, Inc.
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressUS
Party NameBluebird Bio (UK) Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events

Event DateEvent Description
Thursday, April 22, 2021SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, April 23, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, April 27, 2021APPLICATION FILING RECEIPT MAILED
Friday, August 13, 2021CHANGE OF OWNER RECEIVED FROM IB
Thursday, September 9, 2021ASSIGNED TO EXAMINER
Monday, September 20, 2021NON-FINAL ACTION WRITTEN
Tuesday, September 21, 2021NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, October 4, 2021REFUSAL PROCESSED BY MPU
Monday, October 4, 2021NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Saturday, October 9, 2021NEW REPRESENTATIVE AT IB RECEIVED
Saturday, October 30, 2021REFUSAL PROCESSED BY IB
Thursday, March 31, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, March 31, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, April 1, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, April 2, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, May 9, 2022NOTIFICATION PROCESSED BY IB
Tuesday, May 10, 2022PUBLISHED FOR OPPOSITION
Wednesday, April 20, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, April 20, 2022NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, April 20, 2022NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, May 10, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 26, 2022REGISTERED-PRINCIPAL REGISTER
Tuesday, July 26, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
Friday, August 26, 2022CHANGE OF NAME/ADDRESS REC'D FROM IB
Wednesday, October 26, 2022FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Saturday, December 23, 2023CHANGE OF NAME/ADDRESS REC'D FROM IB
Friday, September 13, 2024NEW REPRESENTATIVE AT IB RECEIVED
Monday, December 12, 2022FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, November 1, 2022FINAL DISPOSITION PROCESSED
Wednesday, November 2, 2022FINAL DISPOSITION NOTICE SENT TO IB

Related Keywords

namely adrenoleukodystrophy adrenomyeloneuropathy diseases genetic preparations substances treatment pharmaceutical